Allergan, Inc.

Allergan Sales, Inc.

Allgergan, Inc.

Stephen Donovan

Ping Wang

Gregory F Brooks

Hui Xiang

Mingjiang Luo

Daniel G Brady

Mitchell F Brin

Martin A Voet

Joseph Francis

Yao Yu

Pharmaceutical compositions of a botulinum toxin for oral administration to a patient with a gastrointestinal disorder.

Botulinum toxin formulation for oral administration

Pharmaceutical compositions for transdermal administration of neurotoxins to a patient include a neurotoxin, such as a botulinum toxin, and an enhancing agent that facilitates absorption of the neurotoxin through the skin of the patient and does not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and may be provided in a transdermal patch.

Transdermal botulinum toxin compositions

Combined fence and gate

Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.

Animal product free system and process for purifying a botulinum toxin

Chromatographic processes and systems for purifying atoxin from an APF fermentation medium.

Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.

Clostridial toxin derivatives and methods for treating pain

Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producingbacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.

Media for clostridium bacterium and processes for obtaining a clostridial toxin

Media and processes for the fermentation ofand obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.

Animal product free media and processes for obtaining a botulinum toxin

A method for treating a mammary gland disorder, including hyperplastic, hypertonic, cystic and/or neoplastic mammary gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted breast tissue.

Methods for breast treatment

Methods for treating diverse cancers by local administration of a botulinum toxin to or to the vicinity of the cancer.

Methods for treating diverse cancers

Methods for treating mammary gland disorders

Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.

Growing community of inventors

Capistrano Beach, CA, United States of America

Stephen Donovan